Association between Single-Nucleotide Polymorphism in MicroRNA Target Site of DDB2 and Risk of Hepatocellular Carcinoma in a Southern Chinese Population

Association between Single-Nucleotide Polymorphism in MicroRNA Target Site of DDB2 and Risk of Hepatocellular Carcinoma in a Southern Chinese Population
复制标题

DDB2 MicroRNA 靶位点单核苷酸多态性与中国南方人群肝细胞癌风险的关联

DOI:
10.1155/2020/8528747
复制
发表时间:
2020-02-08
影响因子:
--
通讯作者:
Yu, Hongping
Yu, Hongping
中科院分区:
生物学3区
文献类型:
--
作者:
Qiu, Moqin;Liu, Yingchun;Yu, Hongping

文献摘要

被引文献

相似文献

损伤特异性DNA结合蛋白2(DDB 2)是一种主要参与核苷酸切除修复的DNA修复蛋白,在维持基因组稳定性方面起着关键作用。在本研究中,我们评估了DDB 2基因miRNA靶位点的单核苷酸多态性(SNP)rs 1050244与中国南方人群中1073例肝癌患者和1119例无癌对照的肝细胞癌(HCC)风险的关系。我们的研究结果表明,DDB 2 rs 1050244与HCC风险之间没有统计学显著相关性。在进一步的分析中,按年龄、性别、吸烟、饮酒和HBV感染状况分层,我们发现在非HBV感染人群中,携带SNP rs 1050244的CT/TT基因型的个体与携带CC基因型的个体相比,患HCC的风险显著降低(校正OR = 0.31,95% CI = 0.13-0.72),且该SNP与HBV感染之间存在显著交互作用(P交互作用=0.002)。结果提示DDB 2 rs 1050244 C>T多态性与非HBV感染人群中HCC发病风险降低相关。需要更大样本量的进一步研究来验证我们的发现。
Damage-specific DNA-binding protein 2 (DDB2) is a DNA repair protein mainly involved in nucleotide excision repair, which plays a pivotal role in maintaining genomic stability. In this study, we evaluated the association of single-nucleotide polymorphism (SNP) rs1050244 in miRNA target site of DDB2 gene with risk of hepatocellular carcinoma (HCC) among 1073 HCC patients and 1119 cancer-free controls in a southern Chinese population. Our results showed that no statistically significant association was found between DDB2 rs1050244 and HCC risk. In further analysis stratified by age, sex, smoking, alcohol drinking, and HBV infection status, we found that individuals carrying the CT/TT genotypes of SNP rs1050244 had a significantly decreased risk of HCC compared with those with the CC genotype among non-HBV infected population (adjusted OR = 0.31, 95% CI = 0.13-0.72), and a significant interaction was found between this SNP and HBV infection (Pinteraction=0.002). Our results suggested that the DDB2 rs1050244 C>T polymorphism was associated with the decreased risk of HCC among non-HBV infected population. Further studies with larger sample sizes are needed to validate our findings.